Rank1 | Importance | Informed consent2 | Inclination | Behaviour | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Heart disease | Breast cancer | Depression | Combined | Heart disease | Breast cancer | Depression | Heart disease | Breast cancer | Depression | |
1Higher the ranking more likely a scenario is to elicit the responses of: greater importance, higher rates of requiring informed consent, higher rates of answering ‘less inclined to participate’, and higher rates of ‘would not participate’ based on the conflict of interest information contained in that scenario. The four scenarios with highest average rankings are flagged by the symbols *, †, ‡, and § for ease of visual inspection of trends. As described in the text, rankings are based on a two-way analysis of variance and multiple pair wise comparisons of scenario effects within each column. | ||||||||||
2The results of the informed consent requirement question showed no interaction between scenario and illness so that the rankings are given for the three illness groups combined. | ||||||||||
3–23Scenarios labelled with same superscript numbers show no significant pair-wise scenario differences (p>0.01). Most of the significant pair-wise differences were significant at p<0.0001 level. There were significant interaction effects between scenario and illness for all except the informed consent question, as can be seen from the variations in rankings of the scenario effects depending on the illness group. | ||||||||||
1 | Researcher stocks* | Researcher stocks* | Researcher stocks* | Commercial funding10 | Researcher stocks* | Researcher stocks*14 | Researcher stocks* | Researcher stocks* | Researcher stocks* | Researcher stocks* |
2 | University stocks† | Personal income§5 | University stocks†8 | Researcher stocks*10 | University stocks† | Personal income§14 | Personal income§ | University stocks†18 | University stocks†20 | University stocks†22 |
3 | Researcher patent‡3 | University stocks†5 | Researcher patent‡8 | University stocks† | Researcher patent‡12 | University stocks† | Researcher patent‡16 | Researcher patent‡18 | Researcher patent‡20 | Researcher patent‡22 |
4 | Personal income§3 | Researcher patent‡6 | Personal income§9 | Researcher patent‡11 | Personal income§12 | Researcher patent‡15 | University stocks†16 | Per capita fee19 | Personal income§20 | Personal income§ |
5 | Commercial funding4 | University patent6 7 | University patent9 | University patent11 | Per capita fee13 | Per capita fee15 | Per capita fee17 | Personal income§19 | Per capita fee20 | University patent23 |
6 | University patent4 | Commercial funding6 7 | Commercial funding | Personal income§ | University patent13 | University patent | University patent17 | University patent | Commercial funding21 | Per capita fee23 |
7 | Per capita fee | Per capita fee7 | Per capita fee | Per capita fee | Commercial funding | Commercial funding | Commercial funding | Commercial funding | University patent21 | Commercial funding |